BIO CEO Advisory Committee

  • Recommend
  • Tweet
  • Print
  • Email


John Chambers
Managing Director & Head of Healthcare Investment Banking, ROTH Capital Partners

John Chambers, a Managing Director and Head of Healthcare Investment Banking group, joined ROTH Capital Partners in December 2009. Chambers was formerly the head of Merriman Curhan Ford’s Heath Care and investment banking team. Prior to joining Merriman, Chambers was co-head of investment banking at Rodman & Renshaw. He has also held senior-level health care and biotechnology banking positions at SG Cowen, Lehman Brothers, UBS and Salomon Smith Barney. Chambers has executed a significant number of banking transactions, strategic transactions and restructurings across all health care sectors.

Chambers earned his MBA from Columbia Business School and his BS in mechanical engineering from Union College.


Oleg Nodelman
Founder & Managing Director, EcoR1 Capital

Oleg Nodelman is the Founder and Managing Director of EcoR1 Capital, a San Francisco-based, value-oriented healthcare investment fund.  EcoR1 capitalizes on opportunities in the biotechnology sector and mitigates risk through a highly engaged investment process, emphasizing the value of identifying and recruiting premier human capital in all aspects of corporate management and scientific leadership. 

Prior to EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners L.P., one of the oldest dedicated biotechnology hedge funds.  At BVF, Mr. Nodelman’s responsibilities included all aspects of the business including opportunity generation, deep diligence, portfolio management and trading.  Prior to joining BVF in 2001, Mr. Nodelman was a consultant with Mercer Management Consulting (now Oliver Wyman), a consulting firm focused on strategy, operations, risk management, organizational transformation and leadership development.  At Mercer, he worked with senior management from companies in a variety of industries to develop and implement long-term strategy and build shareholder value. 

Mr. Nodelman is on the Board of Addex Therapeutics (SIX: ADXN) and a is member of the President's Council at the Gladstone Institute. He holds a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University.